 Brickell Biotech Inc NASDAQ: BBI has entered into a definitive agreement with Voronoi Inc for exclusive, worldwide rights to therapeutics generated from a proprietary DYRK1A inhibitor platform. The DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become dysregulated, thus offering potential across a wide array of autoimmune and inflammatory diseases. 